The Missouri Valley Cancer Consortium (MVCC) is a community based research effort with the following specific aims: 1) to provide cooperative group research opportunities to the communities served;2) to provide quality cancer care through ongoing training of health care professionals;3) to promote community awareness of clinical trial availability;4) to educate the community on the importance and safety of clinical trials;5) to provide cancer awareness and cancer prevention education to the community;6) to enroll patients to cooperative group clinical trials. The work of this organization is mainly accomplished through a networking of physicians, nurses, and other health care professionals, hospitals, and community cancer clinics across Nebraska who recognize the unique needs of people with cancer, and who are committed to providing cancer care with an emphasis on research. A desired outcome is that there is direct patient benefit through the clinical trial process, and that there is benefit to the community in the areas of cancer treatment, cancer control, and cancer prevention education. The MVCC has a deeply committed staff of physicians, nurses, and other health care professionals who work together to not only treat cancer patients, but who focus efforts on community awareness of the importance of clinical trials and cancer prevention, using pathways of public education, cancer screening, and cancer prevention education, partnering with organizations such as the American Cancer Society, Leukemia and Lymphoma Society, Komen Foundation, and local programs such as the Nebraska Oncology Society. Strategies to include minority populations in community programs continue to be prioritized. Working in this direction as a program, MVCC has a significant impact on patient care, cancer education, and public awareness of clinical trials within the community. This research program strives to provide access to clinical trials at the community level, to promote quality cancer care and cancer education, and to produce research data that will ultimately benefit all cancer patients.
of this project is that there is direct cancer patient benefit through participation in clinical trials, that the community is educated in the ares of cancer treatment, cancer control, and cancer prevention, and the program produces quality data that assists in meeting the research objectives of the studies being utilized by the program.
|Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55|
|Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade â‰¥ 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:|
|Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32|
|Rule, William G; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. J Geriatr Oncol 6:119-26|
|Dy, Grace K; Molina, Julian R; Qi, Yingwei et al. (2014) NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. J Thorac Oncol 9:1146-53|
|Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27|
|Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83|
|Loprinzi, Charles L; Qin, Rui; Dakhil, Shaker R et al. (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997-1005|
|Dronca, Roxana S; Allred, Jacob B; Perez, Domingo G et al. (2014) Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol 37:369-76|
|Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7|
Showing the most recent 10 out of 137 publications